IGF-1 DES Protocol: Complete Cycling & Dosing Guide

IGF-1 DES Protocol: Complete Cycling & Dosing Guide

Overview

IGF-1 DES (Insulin-like Growth Factor-1 DES(1-3)) is a truncated peptide analog of native IGF-1, modified by the removal of three N-terminal amino acids. This structural modification dramatically increases its potency—approximately 10-fold more active than standard IGF-1—because it cannot bind to IGF-binding proteins (IGFBPs). The result is a peptide that remains in its free, bioactive form at the injection site far longer, enabling highly localized anabolic signaling with theoretically reduced systemic side effects compared to full-length IGF-1 or IGF-1 LR3.

IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling cascades, promoting protein synthesis, myoblast proliferation, and satellite cell activation. Because it's unregulated and not approved for human use, this protocol is presented for educational and research purposes only.

Important: This guide is for informational purposes. IGF-1 DES is a research chemical not approved by the FDA or EMA for human use. Consult a qualified healthcare provider before any research protocol.

Standard Protocol

Typical Dosing Range: 20–100 mcg per injection, administered once to twice daily via intramuscular injection

Injection Frequency:

• Beginner: 20–40 mcg once daily (usually morning)
• Intermediate: 40–60 mcg once daily or split dosing (20–30 mcg twice daily)
• Advanced: 60–100 mcg daily, divided into two injections (morning and evening)

Cycle Structure:

• Standard active cycle: 4–6 weeks on
• Rest period: 2–4 weeks off (minimum 2 weeks to allow receptor downregulation recovery)
• Total cycle: 6–10 weeks (4–6 weeks on + 2–4 weeks off)

Reconstitution (if using lyophilized powder):

1. Use bacteriostatic water or 0.9% sodium chloride solution
2. Inject slowly into the vial to avoid foaming
3. Do not shake; instead, gently roll the vial between your palms for 30–60 seconds
4. Allow 30 minutes for complete dissolution
5. Concentration should be clear and colorless

Storage:

• Before reconstitution: Store lyophilized powder at 2–8°C (refrigerator)
• After reconstitution: Store at 2–8°C; typical usable life is 14–30 days depending on sterility conditions and storage
• Do not freeze reconstituted solution
• Keep away from light to preserve peptide integrity

Goal-Specific Protocols

Protocol A: Localized Muscle Hypertrophy (Primary Use Case)

Goal: Site-specific growth in targeted muscles (chest, shoulders, arms, quadriceps, calves)

Dosing:

• 40–60 mcg per injection
• Inject directly into the target muscle 5–6 days per week
• Perform injection immediately post-training (within 30 minutes of completing the targeted muscle group)
• Single daily injection

Cycle:

• 5 weeks on
• 3 weeks off
• Repeat for up to 3 total cycles (15 weeks total over approximately 6 months)

Expected Response: Localized growth, improved muscle fullness, faster recovery in injected muscle group. Noticeable visual difference typically appears in weeks 3–4.

Protocol B: Systemic Anabolic Support with Minimal Hypoglycemia Risk

Goal: Whole-body muscle-building support without high systemic glucose disturbance

Dosing:

• 30–50 mcg once daily
• Inject into a large muscle group (gluteus maximus, quadriceps, or deltoid)
• Rotate injection sites daily to minimize localized hypoglycemia risk

Cycle:

• 4 weeks on
• 2 weeks off
• Repeat for 2–3 cycles (total 8–12 weeks)

Expected Response: Improved recovery, increased protein synthesis signaling, modest systemic anabolic effect. Risk of hypoglycemia is lower than high-dose protocols due to distributed injections and moderate dosing.

Protocol C: Injury Recovery & Joint Support (Limited Evidence)

Goal: Tissue repair and recovery from acute soft-tissue injury (ligament strain, muscle tear)

Dosing:

• 20–40 mcg per injection
• Inject directly into or adjacent to the injured tissue, 1–2 times daily

Cycle:

• 6–8 weeks continuous
• Then reassess; consider 2-week off periods if using beyond 8 weeks

Note: There is no human evidence that IGF-1 DES improves injury recovery. This protocol is based on mechanistic plausibility only. Monitor closely and discontinue if no improvement is observed after 3–4 weeks.

How to Administer Step-by-Step

Pre-Injection Checklist:

1. Verify reconstitution date and storage conditions
2. Inspect solution for particulates or discoloration (should be clear)
3. Allow solution to reach room temperature if refrigerated
4. Have a meal or glucose source available within arm's reach

Injection Procedure:

1. Prepare the site: Clean injection area with 70% isopropyl alcohol swab using circular motion for 10 seconds; allow to dry completely (30 seconds)

2. Draw the dose: Using a sterile syringe (0.3–0.5 mL insulin syringe or 1 mL syringe), draw the calculated volume. For example: if concentration is 100 mcg/mL and dose is 50 mcg, draw 0.5 mL

3. Position muscle: Relax the target muscle. For intramuscular injection, insert needle at a 90-degree angle, approximately 0.5–1 inch (1.25–2.5 cm) deep depending on muscle size and subcutaneous fat

4. Inject slowly: Depress the plunger steadily over 3–5 seconds; rapid injection increases localized pain

5. Withdraw and apply pressure: Withdraw needle and apply gentle pressure with a clean tissue for 10–15 seconds

6. Post-injection: Remain upright and monitor for dizziness or lightheadedness (signs of hypoglycemia) for 10 minutes. Have carbohydrates available immediately

Injection Sites for Localized Growth:

• Biceps, triceps, forearms
• Chest (pectoral)
• Shoulders (anterior or lateral deltoid)
• Quadriceps, hamstrings, calves
• Glutes (for systemic protocols)

Rotate injection sites daily to prevent repeated localized trauma and to distribute the hypoglycemia risk.

Cycle Example: Week-by-Week Schedule (6-Week Active Cycle + 3-Week Off)

Week 1–6: Active Cycle (50 mcg daily, post-workout injection into target muscle)

| 1 | 50 mcg chest | 50 mcg back | 50 mcg shoulders | 50 mcg legs | 50 mcg arms | 50 mcg chest | Rest | | 2 | 50 mcg chest | 50 mcg back | 50 mcg shoulders | 50 mcg legs | 50 mcg arms | 50 mcg chest | Rest | | 3 | 50 mcg chest | 50 mcg back | 50 mcg shoulders | 50 mcg legs | 50 mcg arms | 50 mcg chest | Rest | | 4 | 50 mcg chest | 50 mcg back | 50 mcg shoulders | 50 mcg legs | 50 mcg arms | 50 mcg chest | Rest | | 5 | 50 mcg chest | 50 mcg back | 50 mcg shoulders | 50 mcg legs | 50 mcg arms | 50 mcg chest | Rest | | 6 | 50 mcg chest | 50 mcg back | 50 mcg shoulders | 50 mcg legs | 50 mcg arms | Rest | Rest |

Week 7–9: Off-Cycle (No injections)

Monitor recovery, assess muscle retention, allow IGF-1R downregulation to reset. This rest period is critical for maintaining sensitivity to the peptide on the next cycle.

What to Expect: Timeline of Effects

Days 1–3:

• Possible mild injection site soreness (resolve with ice and NSAIDs if necessary)
• May feel general malaise or fatigue as signaling cascades begin (expect resolution within 24 hours)

Days 4–7:

• Increased muscle pump during and after training
• Improved recovery (reduced soreness 24–48 hours post-workout)
• Possible transient hypoglycemia symptoms (lightheadedness, hunger) especially post-injection

Week 2–3:

• Noticeable increase in muscle fullness and vascularity in injected areas
• Faster ATP resynthesis; ability to recover between sets may improve
• Appetite may increase (anabolic signaling effect)

Week 3–4:

• Visible increase in muscle size in targeted injection sites
• Improved workout performance and density
• Potential for localized water retention at injection sites (normal and transient)

Week 4–6:

• Maximum anabolic response; growth plateaus if dose remains constant
• Consider dose titration if response flattens (add 10–20 mcg)
• IGF-1R downregulation may begin late in week 5–6, indicating need for off-cycle

Post-Cycle (Week 7–9):

• Muscle loss is minimal if training and nutrition are maintained
• Recovery to baseline takes 7–14 days
• Sensitivity to IGF-1 DES resets, improving response on next cycle

Common Protocol Mistakes

1. Incorrect reconstitution: Shaking the vial aggressively denatures the peptide. Always roll gently. This is the most common mistake and results in severely reduced potency.

2. Injecting into subcutaneous fat instead of muscle: IGF-1 DES requires intramuscular delivery for reliable bioavailability and localized effect. Subcutaneous injection reduces effectiveness and increases systemic effects unpredictably.

3. Failing to rotate injection sites: Repeated injections into the same muscle without rotation causes localized inflammation, increased pain, and inconsistent absorption.

4. Ignoring hypoglycemia symptoms: Lightheadedness, confusion, or extreme hunger post-injection are signs of localized (or systemic) hypoglycemia. Have fast-acting carbohydrates immediately available and reduce dose if symptoms are severe.

5. Running cycles that are too long: Continuous use beyond 6 weeks typically results in IGF-1R desensitization. The mandatory off-cycle is not optional; it allows receptor recovery and maintains peptide efficacy.

6. Poor storage hygiene: Reconstituted peptide stored improperly (freezing, exposure to light, bacterial contamination) loses potency rapidly. Replace if solution appears cloudy or discolored.

7. Combining high IGF-1 DES doses with high systemic insulin: This dramatically increases hypoglycemia risk and is dangerous. If using exogenous insulin, reduce IGF-1 DES dose by 50% or discontinue one compound.

8. Training suboptimally during cycle: IGF-1 DES amplifies the anabolic response to training stimulus. Poor training during an active cycle wastes the peptide's potential. Ensure progressive overload and consistent volume.

How to Stack with Other Compounds

IGF-1 DES + Anabolic Steroids (Testosterone, Nandrolone, Boldenone):

• Synergistic effect on protein synthesis and myoblast proliferation
• Recommended dose: Reduce IGF-1 DES by 20–30% compared to standalone protocol (e.g., 35–45 mcg instead of 50 mcg)
• Stack timing: Begin IGF-1 DES in week 3–4 of steroid cycle when baseline growth rate is established
• Rationale: Steroids prime anabolic machinery; IGF-1 DES amplifies localized response
• Monitor: Increase hypoglycemia risk; keep fast carbs available at all times

IGF-1 DES + Growth Hormone (GH, 4–8 IU daily):

• Additive anabolic effects; GH increases endogenous IGF-1 production, IGF-1 DES provides localized boost
• Recommended dose: Standard IGF-1 DES dosing (40–60 mcg); no reduction necessary
• Stack timing: Can overlap fully; both compounds are complementary
• Monitor: Systemic hypoglycemia risk increases; maintain frequent carbohydrate availability
• Expected benefit: Accelerated recovery, increased hyperplasia (new muscle fiber formation), superior body composition changes

IGF-1 DES + Insulin:

• Caution: High-risk combination. Synergistic hypoglycemia effect
• Recommended dose: If combining, reduce IGF-1 DES to 20–30 mcg maximum
• Timing: Inject IGF-1 DES 15 minutes before exogenous insulin to avoid simultaneous glucose-lowering
• Monitor: Check blood glucose frequently; have dextrose or fast-acting carbs immediately available
• Not recommended for users without extensive metabolic monitoring capability

IGF-1 DES + Thyroid Hormones (T3, T4):

• Minimal direct interaction; thyroid hormones increase metabolic rate while IGF-1 DES promotes anabolism
• Recommended dose: No adjustment needed
• Expected benefit: Improved nutrient partitioning (more carbs/amino acids directed to muscle)
• Monitor: Ensure adequate caloric intake; thyroid hormones + IGF-1 DES can create aggressive energy deficit if calories are insufficient

IGF-1 DES + SARMs (Selective Androgen Receptor Modulators):

• Complementary mechanisms; SARMs provide androgen-like effects, IGF-1 DES drives localized growth
• Recommended dose: Standard IGF-1 DES (40–60 mcg); no reduction
• Stack timing: Overlap fully
• Monitor: Standard hypoglycemia precautions
• Expected benefit: Dry gains (less water retention), preserved muscle on caloric deficit, localized hypertrophy

IGF-1 DES + Exogenous Peptides (GHRP-6, Ipamorelin, CJC-1295):

• Complementary; GH secretagogues raise endogenous IGF-1 and GH, IGF-1 DES provides direct receptor activation
• Recommended dose: Standard IGF-1 DES (40–60 mcg)
• Stack timing: Administer GH secretagogues in evening before bed; IGF-1 DES post-training
• Expected benefit: Enhanced recovery, improved anabolism during sleep + training
• Monitor: Standard precautions

Protocol Quick Reference Table

Signs It's Working (Efficacy Markers)

1. Accelerated recovery: Muscle soreness (DOMS) resolves 24 hours faster than baseline
2. Improved pump: Muscle fullness